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A b s t r A c t
Hypertrophic Cardiomyopathy (HCM) is a genetic disease caused by a variety 
of mutations in proteins, mostly but not exclusively, of the cardiac sarcomere. It is 
characterized by hypertrophy of the left ventricle (LV), often with obstruction of the 
LV outflow tract (LVOT), in the absence of another cause, such as hypertension or 
aortic stenosis, capable of producing the degree of hypertrophy observed. It presents 
with markedly variable morphologic and hemodynamic abnormalities and clinical 
manifestations. The present review will briefly summarize the genetics, pathophysi-
ology, clinical features and management of this disease and will mainly deal with 
the non-surgical reduction of septal hypertrophy by means of transcoronary alcohol 
septal ablation.
G E N E t I c  s U b s t r A t E
HCM is inherited as an autosomal dominant trait and it constitutes the most com-
mon genetic cardiovascular disease, affecting about 0.2% of the general population 
[1]. Eleven mutations involving sarcomeric genes have been identified so far, the most 
common being beta myosin heavy chain and myosin-binding protein C. Moreover, 
there are several different mutations in each gene, the total number exceeding 400 
[2]. Additionally, two non-sarcomeric protein mutations affecting cardiac metabolism, 
have been identified with a phenotype similar to HCM [3]. The progress in molecular 
genetics have permitted the detection of mutated genes, thus providing a genetic diag-
nosis even in asymptomatic relatives of patients with HCM, allowing better counseling 
as well as recognition of a greater number of affected individuals.
P A t H O L O G Y ,  P A t H O P H Y s I O L O G Y  A N D  c L I N I c A L 
m A N I f E s t A t I O N s
The mutations in contractile protein genes appear to be directly affecting sarcom-
ere function, leading to the characterization of HCM as a “disease of the sarcomere”. 
The hypertrophy of the LV is a consequence of sarcomeric dysfunction. Myocyte 
disarray with loss of parallel arrangement, abnormal intercellular connections and 
variation between individual myocytes constitute the major histopathologic findings. 
The macroscopic result is a usually asymmetric LV hypertrophy, involving the septum 
more than the free walls. There is a substantial diversity regarding the distribution and 
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magnitude of LV hypertrophy even between close relatives. 
The right ventricle is involved in 30% of cases. Frequently, an 
abnormal mitral valve with elongation of leaflets or anomalous 
insertion of the papillary muscles may also be present [4].
In patients with HCM, the left ventricle exhibits a hyper-
dynamic systolic function maintaining a small cavity. LVOT 
obstruction occurs in 30-50%, causing a gradient between 
the LVOT and the aorta, sometimes at rest and sometimes 
only with drugs or maneuvers. The main mechanism involves 
a systolic anterior motion (SAM) of the mitral leaflets due 
to a suctioning effect that pulls them towards the hypertro-
phied septum (i.e. a Venturi effect) [1]. The resulting mitral 
regurgitation is usually mild to moderate and eccentric. On 
the contrary, when primary mitral valve disease exists, the 
direction of the regurgitant jet is usually central and of vary-
ing magnitude. 
Diastolic function is also affected in 80% of patients, 
with a prolonged rapid filling phase and an increased atrial 
contribution, showing impaired LV relaxation. It constitutes 
a major cause of symptoms of dyspnea and exercise limitation 
both in obstructive and non-obstructive HCM [2]. 
Many patients with HCM are asymptomatic and are 
often diagnosed during family screening. When symptoms 
do develop, they are usually one or more of the following: 
Dyspnea on exertion and occasionally orthopnea or paroxys-
mal nocturnal dyspnea, chest pain, presyncope and syncope, 
palpitations and fatigue [5]. The degree of obstruction is not 
predictably correlated with symptoms. Some patients with 
severe LV outflow tract obstruction remain asymptomatic 
for many years, while cardiac arrest or sudden death may 
be the initial presentation of the disease, thus underscoring 
the importance of family screening. Syncope may be due to 
conduction diseases, paroxysmal arrhythmias or abnormal 
vascular responses such as inappropriate vasodilatation in 
non-exercising muscles and reflex dilatation of venous beds 
triggered by LV baroreceptors [1]. Myocardial ischemia may be 
due to increased oxygen demand due to hypertrophy, thicken-
ing and narrowing of small intramural vessels and systolic com-
pression of larger perforator and epicardial vessels. The most 
common arrhythmia in patients with HCM is paroxysmal or 
chronic atrial fibrillation (AF), both symptom-compromising 
and increasing risk of embolic events [6]. Other arrhythmias 
include ventricular ectopic beats and non-sustained VT in 
ambulatory ECG. 
N A t U r A L  H I s t O r Y  A N D  P r O G N O s I s
The clinical course of HCM is quite variable and it may 
run asymptomatic for the majority of patients over long periods 
of time. The annual mortality rate is roughly 1% per year and 
is somewhat higher in children [1,4]. Those patients who have 
symptoms upon presentation have a greater annual rate of car-
diac death (0. versus 1. percent, p<0.05) and sudden death 
(1.4 versus 0.1 percent, p<0.05), compared to asymptomatic 
patients [7]. A small proportion of patients with HCM even-
tually progress to a stage, with reduced LV systolic function 
with dilation and wall thinning, resembling the morphologic 
and functional features of dilated cardiomyopathy, called 
“end-stage” or “burned out” HCM [8]. 
m A N A G E m E N t
A .  P r E v E N t I O N  O f  s U D D E N  c A r D I A c  D E A t H
Patients with HCM are prone to both atrial and ven-
tricular arrhythmias, the incidence of which increases with 
age. However the majority of these are not life-threatening. 
Ventricular tachycardia and fibrillation can cause sudden 
cardiac death (SCD), most commonly during adolescence 
and young adulthood. It should be noted that many of these 
patients were totally asymptomatic and sudden cardiac death 
was the first manifestation of the disease. Moreover, HCM is 
the most common cause of death among young athletes []. 
The major risk factors for SCD are a prior cardiac arrest or 
sustained VT, a family history of HCM-related death, syncope 
especially during exertion, a hypotensive response to exercise, 
multiple episodes of non-sustained VT in ambulatory Holter 
monitoring, massive LV hypertrophy (>30 mm), presence of 
an LV apical aneurysm and the end-stage disease with LV 
systolic dysfunction [10]. Certain mutations such as, beta 
myosin heavy chain and troponin T, are also associated with 
premature death more than others [11]. 
The implantation of a cardioverter-defibrillator (ICD) is 
the preferred therapy for HCM patients at high-risk of SCD, 
both for secondary (i.e. implantation after cardiac arrest) 
and primary prevention, in patients with one or more high 
risk factors [12]. The role of antiarrhythmic drugs is limited 
to patients with an ICD who experience frequent episodes, or 
as an alternative to an ICD, in high-risk patients who are not 
candidates for or choose not to have an ICD.
b .  m E D I c A L  t r E A t m E N t
For heart failure symptoms due to diastolic dysfunction or 
LVOT obstruction, beta-blockers have been extensively used 
with excellent results both in obstructive and non-obstruc-
tive HCM, since they block catecholamines, thereby reduc-
ing LVOT gradient and improving diastolic filling time and 
relaxation. Verapamil may also provide symptomatic benefit 
for similar reasons but a number of patients with elevated ve-
nous pulmonary pressures may experience pulmonary edema 
and SCD [2]. Disopyramide has also been proven effective, 
especially in combination with beta-blockers owing to its 
negative inotropic effects and no evidence of proarrhythmia 
in these patients [13]. When atrial fibrillation complicates 
the clinical course of HCM it requires aggressive interven-
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tion with anticoagulation, attempts to restore sinus rhythm, 
both pharmacological and electrical, and consideration of 
catheter ablation of the pulmonary veins and the surgical 
maze procedure [2]. 
N O N - m E D I c A L  t r E A t m E N t
Pharmacologic therapy is the first-line treatment for 
symptomatic patients with LVOT obstruction. For those pa-
tients that prove to be refractory to medical therapy, surgical 
myectomy, dual-chamber pacing and, more recently, ethanol 
ablation of the hypertrophied septum, have all been tried with 
variable results. It has been estimated that these approaches 
are required in approximately 5% of all patients with HCM 
and up to 30% in tertiary referral centers [1,14]. 
1. Dual Chamber Pacing
Dual chamber pacing has been used in the past as an 
alternative to surgery, but studies have not shown objective 
evidence of gradient reduction and improvement of exercise 
capacity [1,4]. It is now primarily performed in patients un-
dergoing ICD implantation, as well as selected older patients 
(more than 65 years of age), or those with other indications 
for pacing. The rationale behind dual-chamber pacing is that, 
by initiating the signal in the right ventricular apex, it alters 
the sequential contraction of the basal septum, thus reducing 
the gradient.
2. Surgical myectomy
Surgery for HCM has been a well established therapeutic 
option for over 40 years. The Morrow procedure involves the 
resection of a small portion of the basal interventricular sep-
tum (2 to 11 gm) and has shown excellent results in reducing 
LVOT gradient, improving symptoms and reducing mitral 
regurgitation, but also in reducing mortality risk in severely 
symptomatic patients with obstructive HCM [15]. Although 
earlier reports mentioned a mortality rate of 4%-6% [16,17], 
more recent studies report mortality rates of less than 2% 
[15,18]. The surgical results are much improved due to better 
anesthesia, myocardial protection during cardio-pulmonary 
bypass, and the use of intra-operative transesophageal 
echocardiography [1]. The latter permits a thorough evalu-
ation of the surgical result upon the interventricular septum 
and, if required, the mitral valve, before the patient leaves 
the operating room. 
Complications of surgical myectomy include ventricular 
septal defect due to excessive removal of cardiac muscle, aor-
tic regurgitation due to the transaortic approach and LBBB 
or complete heart block requiring a permanent pacemaker 
[20-22]. 
3. Alcohol Septal Ablation (ASA)
Non-surgical reduction therapy (NSRT), or alcohol septal 
ablation (ASA), or transcoronary ablation for septal hypertro-
phy (TASH), or percutaneous transluminal septal myocardial 
ablation (PTSMA), are all equivalent terms, referring to the 
creation of an iatrogenic septal infarct via alcohol injection 
in a perforating septal branch of the left anterior descending 
artery (LAD). Since it was first introduced in 15 [23] it has 
been used as a therapeutic option alternative to surgery. The 
initial concept was conceived after recognizing that spontane-
ous anterior myocardial infarctions in HCM patients resulted 
in reducing the LVOT gradient. Nowadays more than 3500 
patients have undergone the procedure [24]. 
The appropriate selection criteria for patients’ suitabil-
ity for alcohol septal ablation (ASA) are described in the 
ACC/ESC Expert Consensus Document on hypertrophic 
cardiomyopathy (see Table 1). It is important to note that for 
asymptomatic or slightly symptomatic patients, given their 
relatively low risk of sudden cardiac death if they don’t pos-
sess any high risk factors, probably aggressive intervention is 
not justified although there are not enough data to address 
the question, [25]. Another important issue is the approach 
to patients with obstruction and one or more high risk factors. 
For this subgroup of patients it would be reasonable to implant 
an ICD and reevaluate the effect of sequential AV pacing on 
LVOT gradient and then, if still symptomatic, consider alcohol 
septal ablation or surgery [1].
The main parts of the procedure are as follows: After the 
insertion of a temporary pacemaker in the right ventricular 
apex, for the possibility of complete heart block, a left heart 
catheterization is performed, starting with a multipurpose 
catheter to measure the LV gradient by a pull-back method 
[26]. This is followed by coronary angiography to identify 
the septal perforator branches of the LAD. An over-the-
wire balloon catheter is introduced and inflated into those 
branches and contrast medium is injected into the balloon 
catheter lumen. Contrast echocardiography is then performed 
in order to identify the area supplied by the specific branch 
and thus select the most suitable for infarction. The use of 
echocardiography also ensures that the contrast goes only to 
the septum, close to the point of its contact with the mitral 
valve, and not elsewhere such as the papillary muscles, the LV 
free wall or the right ventricle. A small amount of absolute 
ethanol (usually 1-3 ml) is then injected very slowly and the 
inflation is maintained for a few minutes. Subsequently, a new 
angiography is done to ensure LAD patency and the occlusion 
of the target branch. Finally, the intraventricular gradient is 
remeasured to assess the acute effect of the procedure. It 
should be noted that the LVOT gradient in the acute phase 
is reduced, probably due to a stunning effect, and in the next 
few days gradually increases, possibly due to edema, until it 
finally falls over a period of weeks, due to scar formation [24]. 
This has been called a ‘triphasic’ response.
The main complications arising from alcohol septal abla-
tion are summarized in Table 2 [27]. The in-hospital death 
may range from 1% to 4% but in specialized centers may be 
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as low as 1% [27-2]. The incidence of complete heart block 
(CHB) requiring a permanent pacemaker insertion was very 
high in the initial reports but it is now estimated between 
14%-25% [30-35]. The introduction of myocardial contrast 
echocardiography, lower ethanol doses and ethanol infusion 
instead of bolus injection have all contributed to better results. 
A report from Mayo clinic [22], found that from 58 patients 
undergoing ethanol septal ablation 12% developed CHB and 
36% developed right bundle brunch block (RBBB). The fig-
ures among 117 patients undergoing surgical myectomy were 
3% for CHB and 40% for left bundle brunch block (LBBB). 
It appears that ASA produces a transmural infarction of the 
basal mid septum and adjacent RBB, whereas surgery affects 
the basal anterior septum and adjacent LBB [22]. These ob-
servations are of particular importance in selecting patients 
for invasive treatment, as for example, a preexisting LBBB in 
a patient undergoing ASA is a high risk factor for the develop-
ment of CHB. Nevertheless, the benefit from ASA does not 
appear to be less in patients who develop CHB compared to 
those who do not [33].
The potential risk of ventricular septal rupture has been 
reported just once [36] and was successfully treated with an 
Amplatzer ventricular septal defect closure device. Other 
dangerous complications include LAD dissection, peripro-
cedural ventricular arrhythmias including fibrillation and 
pericardial effusion, but they are not often reported and can 
be dealt with successfully. 
The concern about the possibility of long-term ventricular 
arrhythmias due to myocardial scaring has also been raised 
[37]. The in-hospital malignant arrhythmias can be probably 
attributed to ischemia, but there have been reports of ven-
tricular tachycardias in follow-up [38,3]. Nevertheless, the 
reduction of LVOT gradient and the subsequent regression in 
LV hypertrophy, due to ASA may also exert an antiarrhythmic 
effect [26]. A study of ventricular arrhythmias in patients al-
ready having an ICD did not show increased episodes [40].
The beneficial effects of ASA have been well documented 
over the last decade. It appears that septal ablation reduces 
LVOT gradient, increases exercise capacity and peak oxygen 
consumption and reduces NYHA class [41,42]. There is also 
a favorable effect on LV regional asynchrony, which accounts 
for the acute improvement in LV relaxation, as shown by tissue 
Doppler imaging [43]. The long-term benefits derive from the 
localized septal infarction and the subsequent scar formation, 
which results in an increase in LVOT diameter and a decrease 
in LV mass and the extent of hypertrophy. Such a therapeutic 
remodeling of the left ventricle results in the observed clinical 
benefits [44,45]. A reduction in nonseptal mass over time after 
ethanol septal ablation has been observed that may indicate 
that a degree of myocardial hypertrophy in HCM is in part 
afterload-dependent, due to the excessive septal hypertrophy, 
and is not entirely due to the genetic defect [44,45]. There is 
also a beneficial effect on mitral regurgitation [30,42]. Several 
studies have documented the beneficial effects of alcohol sep-
tal ablation on the left ventricular diastolic properties [46,47]. 
A shortening of isovolumic relaxation time and transmitral 
early diastolic deceleration time along with an increase in 
transmitral flow propagation velocity have been attributed to 
an improved relaxation profile of the left ventricle [47]. A great 
part of the observed benefit is due to the continuous regression 
of LV hypertrophy as shown by Mazur et al [44]. Finally, an 
improvement in the Tei Doppler index was shown in mid-term 
follow-up of patients who had undergone ASA [48]. 
Nevertheless, weaknesses of the procedure began to 
emerge shortly after its introduction in clinical practice. 
Younger patients with greater thickness in the interventricular 
septum were found to have a lesser degree of LVOT gradient 
reduction after septal ablation [4]. Similar, unsatisfactory 
results were reported by Faber et al [50]. Moreover, in a sub-
stantial number of cases, a suitable branch for alcohol infusion 
may not be found [51,52]. This would obviate the need for 
patient referral for surgical treatment. 
As regards the comparison of alcohol ablation therapy 
with surgical myectomy, it should be noted that there are no 
randomized controlled trials. Such a trial would enlighten 
the medical community regarding the appropriate selection 
tAbLE 1. Indications for ASA
Symptoms, functional class III to IV
Severe side effects of medical treatment
LVOT pressure gradient (maximum gradient) >30(50) mmHg
Provokable LVOT pressure gradient (maximum gradient) 
>50(100) mmHg
Systolic anterior motion related obstruction
Mid-cavitary obstruction
Septal thickness >15(18) mm
Suitable septal branch
tAbLE 2. Periprocedural complications of alcohol septal 
ablation
Early mortality (within 30-days) 1.5% (0-5%)
Ventricular fibrillation 2.2%
LAD dissection 1.8%
Pericardial effusion 0.6%
Complete heart block requiring pacing 10.5%
Need for repeat ASA 6.6%
Need for surgical myectomy 1.%
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of patients for each method. The practical problems that 
arise make such a possibility quite distant [53]. The different 
morphologic effects of the two procedures were shown in a 
recent prospective study of 48 patients using cardiac magnetic 
resonance (CMR). While myectomy resulted in a discrete area 
of resected tissue in the anterior septum, alcohol ablation 
caused tissue necrosis more inferiorly and extending into the 
right septal side at the midventricular level, thereby producing 
a more variable effect [54]. 
With respect to the clinical outcomes both methods have 
proven efficacy .In a report from the Cleveland clinic, the 
authors concluded that both interventricular septal thick-
ness and LVOT gradient were reduced and NYHA class was 
significantly improved in patients with obstructive HCM [30]. 
A similar study showed similar hemodynamic and functional 
improvements at one year in patients with a resting LVOT gra-
dient at least 40 mmHg, who were severely limited by dyspnea 
or angina or had recurrent limiting presyncope or syncope 
[31]. A more recent study comparing outcomes after ablation 
or myectomy showed significantly lower postintervention LV 
outflow gradients at rest and with provocation in the myectomy 
group accompanied by reduced systolic anterior motion of the 
mitral valve and improved NYHA class [55]. 
c O N c L U s I O N
Both surgical myectomy and alcohol septal ablation are 
effective treatments for highly symptomatic patients with 
HOCM. Due to the lack of randomized controlled trials for di-
rect comparison, physicians need to consider the advantages of 
each one when selecting patients for septal reduction therapy. 
Advantages of the ablation technique include the avoidance 
of a major surgical procedure, the lack of post-operative pain 
and need for transfusion, the shorter hospital stay and the low 
incidence of atrial fibrillation [24]. Advantages of the surgical 
technique are the immediate and permanent relief of ouflow 
gradient, the less need for a permanent pacemaker, the fact 
that coexisting mitral and coronary artery disease can be dealt 
with at the same time and the proven long-term efficacy. For 
the ablation procedure such long-term data are lacking [56] 
and moreover the question of the possible arrhythmic risk due 
to scar formation remains unanswered. As noted by Maron 
et al, although there is an increasing enthusiasm for the abla-
tion procedure among interventional cardiologists, we should 
remember that surgery is the most effective and long-lasting 
treatment for alleviating symptoms of obstructive HCM and 
therefore it should be regarded as the primary treatment op-
tion for drug-refractory symptomatic patients [2]. 
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